ARTES Biotech­nol­o­gy announces the acqui­si­tion of the unique Split­Core tech­nol­o­gy devel­oped by sci­en­tists at the Uni­ver­si­ty of Freiburg, Germany.

Back­bone of this plat­form is a flex­i­ble inte­gra­tion and pre­sen­ta­tion of for­eign anti­gens on the sur­face of cap­sid virus like par­ti­cles (cVLP), which can be pro­duced in bac­te­ria and yeast.

With its yeast based METAVAX® plat­form for anti­gen pre­sen­ta­tion on enve­lope virus like par­ti­cles (eVLP´s), ARTES is already well estab­lished and a pre­ferred part­ner for human and ani­mal vac­cine devel­op­ment projects. The inclu­sion of the Split­Core tech­nol­o­gy in ARTES’ vac­cine devel­op­ment port­fo­lio enables the com­pa­ny to offer cus­tomers an even broad­er spec­trum of ser­vice solu­tions for the devel­op­ment of their spe­cif­ic vaccines.

With the two potent and ver­sa­tile plat­forms, Split­Core and METAVAX®, we can now offer the full range of nanopar­ti­cle based vac­cine devel­op­ment, cov­er­ing both cap­sid VLP’s and enve­lope VLP´s. Anti­gens, rang­ing from pep­tide epi­topes to com­plex pro­teins, are com­pat­i­ble with these tech­nolo­gies and can be man­u­fac­tured in all major recom­bi­nant pro­duc­tion plat­forms includ­ing E. coli, yeast and CHO cells”, Volk­er Jen­zelews­ki, Direc­tor Tech­nol­o­gy of ARTES, said. “Split­Core will sub­stan­tial­ly com­ple­ment our capa­bil­i­ty to address tech­ni­cal and eco­nom­i­cal chal­lenges our phar­ma­ceu­ti­cal cus­tomers may face. Togeth­er with our METAVAX® plat­form, which already result in sev­er­al vac­cine can­di­dates man­u­fac­tured, we are now even stronger posi­tioned to sup­port the devel­op­ment of inno­v­a­tive vaccines.”

Split­Core bases on the tech­nol­o­gy to split the core or cap­sid pro­tein of Hepati­tis B virus into two parts. These split­ted core anti­gens form effi­cient­ly nanopar­ti­cles known as cap­sid virus like par­ti­cles (cVLP). On the sur­face of those par­ti­cles, dif­fer­ent­ly struc­tured pro­teins can be added with a high degree of free­dom and will then be pre­sent­ed high­ly exposed and hence effec­tive to the immune system.